ETR:EVT

Evotec (EVT) Stock Forecast, Price & News

€18.66

-0.47 (-2.46%)

(As of 09/26/2023 ET)

Compare

Today's Range: €18.66
▼
€19.60
50-Day Range: €19.27
▼
€24.24
52-Week Range: €14.80
▼
€24.44

Volume: 516,956 shs
Average Volume: 1.36 million shs
Market Capitalization: $3.31 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: €28.00

Profile Analyst Ratings Chart Competitors Headlines

About Evotec (ETR:EVT) Stock

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

EVT Price History

30 days | 90 days | 365 days | Advanced Chart

EVT Stock News Headlines

September 26, 2023 | finance.yahoo.com

Evotec and Novo Nordisk Launch LAB eN(2) to Accelerate Translation in Cardiometabolic Diseases

August 29, 2023 | markets.businessinsider.com

EQS-News: Evotec SE reports results for the first half-year 2023 and provides corporate updates

September 27, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.

July 28, 2023 | markets.businessinsider.com

EQS-Adhoc: Evotec provides update on financial impact of cyber-attack

July 28, 2023 | markets.businessinsider.com

EQS-News: Evotec provides update on financial impact of cyber-attack

July 11, 2023 | markets.businessinsider.com

EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership

June 29, 2023 | finanznachrichten.de

Evotec SE: Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme

June 20, 2023 | markets.businessinsider.com

EQS-News: Evotec SE Annual General Meeting 2023 approves all proposed agenda items

September 27, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

June 20, 2023 | finance.yahoo.com

Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items

June 8, 2023 | markets.businessinsider.com

Citi upgrades Evotec AG (EVO) to a Buy

June 8, 2023 | msn.com

WARBURG RESEARCH GMBH Maintains Evotec SE (FWB:EVT) Buy Recommendation

June 5, 2023 | finanznachrichten.de

Evotec SE: Evotec Presents Sustainability Strategy

June 5, 2023 | markets.businessinsider.com

EQS-News: Evotec presents sustainability strategy

June 2, 2023 | finanznachrichten.de

Evotec SE: Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics

May 9, 2023 | markets.businessinsider.com

EQS-Adhoc: Just Evotec Biologics enters strategic biosimilars partnership with Sandoz

May 9, 2023 | markets.businessinsider.com

EQS-News: Just Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing

May 9, 2023 | finance.yahoo.com

Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing

April 10, 2023 | markets.businessinsider.com

EQS-News: Evotec SE provides update on cyber attack

March 28, 2023 | uk.finance.yahoo.com

Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership

March 28, 2023 | finanznachrichten.de

Evotec SE: Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership

March 28, 2023 | markets.businessinsider.com

EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership

March 28, 2023 | finance.yahoo.com

Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership

March 28, 2023 | markets.businessinsider.com

EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' very strong performance in a challenging year

March 28, 2023 | finance.yahoo.com

Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year

March 24, 2023 | markets.businessinsider.com

EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis

March 24, 2023 | finanznachrichten.de

Evotec SE: Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis

See More Headlines

Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ETR
Industry: Drug Manufacturers—Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: ETR:EVT
CUSIP: N/A
CIK: N/A
Web: www.evotec.com
Phone: +49-40-560810
Fax: N/A
Employees: 5,067
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: €28.00
High Stock Price Forecast: €34.00
Low Stock Price Forecast: €21.00
Forecasted Upside/Downside: +50.1%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): (€0.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 16.69
P/E Growth: 0.98
Net Income: $-103,300,000.00
Net Margins: -12.94%
Pretax Margin: N/A
Return on Equity: -8.43%
Return on Assets: 1.21%

Debt

Debt-to-Equity Ratio: 45.49
Current Ratio: 2.10
Quick Ratio: 2.97

Sales & Book Value

Annual Sales: $798.41 million
Price / Sales: 4.14
Cash Flow: €5.40 per share
Price / Cash Flow: 3.45
Book Value: €6.64 per share
Price / Book: 2.81

Miscellaneous

Outstanding Shares: 177,190,000
Free Float: N/A
Market Cap: $3.31 billion
Optionable: Not Optionable
Beta: 1.04

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Werner Lanthaler M.B.A. (Age 55)
MBA, MPA, Ph.D., Chairman of Management Board & CEO
Comp: $1.32M

Dr. Cord Dohrmann Ph.D. (Age 59)
Chief Scientific Officer & Member of Management Board
Comp: $804k

Dr. Craig Johnstone Ph.D. (Age 53)
COO & Member of Management Board
Comp: $712k

Dr. Matthias Evers Ph.D. (Age 50)
Chief Bus. Officer & Member of Management Board
Comp: $636k

Ms. Laetitia Rouxel (Age 49)
CFO & Member of Management Board

Ms. Anja Bosler
Principal Accounting Officer and Sr. VP of Group Accounting

Mr. Volker Braun
Sr. VP and Global Head of Investor Relations & ESG

Dr. Christian Dargel
EVP Global Head of Legal & Compliance

Gabriele Hansen
Sr. VP & Head of Global Corp. Communications & Marketing

Ms. Monika Conradt
Global Head of HR

Key Competitors

View All Competitors

EVT Stock - Frequently Asked Questions

What is Evotec's stock price forecast for 2023?: 0 equities research analysts have issued 1 year price objectives for Evotec's stock. Their EVT share price forecasts range from €21.00 to €34.00. On average, they predict the company's share price to reach €28.00 in the next year. This suggests a possible upside of 50.1% from the stock's current price.
View analysts price targets for EVT or view top-rated stocks among Wall Street analysts.
How have EVT shares performed in 2023?: Evotec's stock was trading at €15.26 at the beginning of the year. Since then, EVT shares have increased by 22.2% and is now trading at €18.66.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Evotec own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC).
What is Evotec's stock symbol?: Evotec trades on the ETR under the ticker symbol "EVT."

What is Evotec's stock price today?: One share of EVT stock can currently be purchased for approximately €18.66.
How much money does Evotec make?: Evotec (ETR:EVT) has a market capitalization of $3.31 billion and generates $798.41 million in revenue each year. The company earns $-103,300,000.00 in net income (profit) each year or (€0.57) on an earnings per share basis.
How many employees does Evotec have?: The company employs 5,067 workers across the globe.
How can I contact Evotec?: Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The official website for the company is www.evotec.com. The company can be reached via phone at +49-40-560810.

This page (ETR:EVT) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial